Trial Profile
A Phase 4, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety of 2 New of 6:2 Influenza Virus Reassortants in Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2019
Price :
$35
*
At a glance
- Drugs MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 13 Jul 2018 Planned End Date changed from 19 Dec 2018 to 27 Dec 2018.
- 13 Jul 2018 Planned primary completion date changed from 19 Dec 2018 to 27 Dec 2018.